AstraZeneca’s Tagrisso exhibited overwhelming efficacy benefit for patients with unresectable, stage III EGFR-mutated lung cancer in LAURA phase III trial

The LAURA phase III trial highlights AstraZeneca's Tagrisso (osimertinib) as a promising intervention, demonstrating a statistically significant improvement in progression-free survival (PFS) for unresectable Stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT) compared to a placebo. While overall survival (OS) data is not yet mature, a favorable trend is observed and will be further assessed. Globally, 2.4 million are diagnosed with lung cancer annually, with 80-85% having NSCLC. Approximately 10-15% (US/Europe) and 30-40% (Asia) exhibit EGFR mutations, impacting one in six NSCLC patients with unresectable Stage III disease.

Tagrisso's safety in the LAURA trial aligns with its established profile. Approved in over 100 countries, Tagrisso's efficacy extends across various stages of EGFRm NSCLC. The ongoing commitment involves neoadjuvant and adjuvant trials, addressing early-stage disease. As a founding member of the Lung Ambition Alliance, AstraZeneca strives for global collaboration, working toward innovative solutions and advancements in lung cancer treatment. Research initiatives like SAVANNAH and ORCHARD explore resistance mechanisms, emphasizing AstraZeneca's dedication to revolutionizing oncology and enhancing patient outcomes.